This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vision-Sciences Reports First Quarter 2014 Financial Results

ORANGEBURG, N.Y., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI) today announced financial results for the first quarter of fiscal 2014, ended June 30, 2013. Highlights include:
  • Net sales increased 8% to $3.7 million, compared with $3.4 million in the first quarter of fiscal 2013;
  • Gross profit improved by 18% to $1.1 million, compared with $0.9 million in the first quarter of fiscal 2013;
  • Net loss improved by 8% to $2.4 million, or ($0.05) per basic and diluted share, compared to $2.6 million, or ($0.06) per basic and diluted share, in the first quarter of fiscal 2013;
  • Launched the 7000 Series Vision System ® video processor platform, worldwide; and,
  • Appointed Howard I. Zauberman as Interim Chief Executive Officer effective May 13, 2013.

"Since joining Vision Sciences in mid-May, I have been conducting a comprehensive strategic assessment of our business," said Howard Zauberman, Interim Chief Executive Officer. "Thus far, I have realigned the Company's direct sales efforts to focus on those markets and customers where we have primarily had success, strong brand recognition and product loyalty. In particular this has been in the ENT and TNE markets in the office setting, and critical care/pulmonology in the ICU setting."

Mr. Zauberman continued, "With respect to our partnership with Stryker Urology, we are pleased with their ongoing progress. With top-line growth and a reduction of our net loss, this quarter was the first step towards strengthening our foundation and building a long-term plan that rewards shareholders. We will do this by fostering a culture of innovation to fully realize the commercial potential of this Company."

First Quarter Financial Results               

Net sales in the first quarter of fiscal 2014 were $3.7 million, an increase of $0.3 million, or 8%, over the first quarter of fiscal 2013.
  • Medical segment sales increased 21%, primarily due to a 76% increase in sales to the urology market as compared to the prior year quarter. The increase was primarily attributable to shipments of our flexible ureteroscope to Stryker; and, 
  • Industrial segment sales decreased 31%, primarily due to an atypically large order that shipped in the first quarter last year; there was no comparable order in the first quarter of fiscal 2014. 

Net sales detail (in thousands, except for percentages) for the three-month periods were as follows:
  Three Months Ended  
  June 30,  
Market/Category 2013 2012 Change
Urology  $ 1,862  $ 1,056 76%
ENT /TNE 542 608 -11%
Pulmonology 87 125 -30%
Spine -- 259 -100%
Repairs, peripherals, and accessories 538 448 20%
Total medical sales 3,029 2,496 21%
Borescopes 337 631 -47%
Repairs 286 269 6%
Total industrial sales 623 900 -31%
Net sales  $ 3,652  $ 3,396 8%
Product – medical sales      
Endoscopes  $ 1,561  $ 1,493 5%
EndoSheath technology 930 555 68%
Repairs, peripherals, and accessories 538 448 20%
Total medical sales  $ 3,029  $ 2,496 21%

Gross profit increased by $0.2 million, or 18%, to $1.1 million in the first quarter of fiscal 2014. Gross margin for the 2014 quarter increased 300 basis points to 30% from 27% in the first quarter of fiscal 2013 due to favorable manufacturing absorption driven by higher production volume in the 2014 fiscal period.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.24 -0.99%
FB $118.04 0.52%
GOOG $696.39 0.58%
TSLA $230.84 -0.64%
YHOO $35.90 -0.31%


Chart of I:DJI
DOW 17,700.78 -50.13 -0.28%
S&P 500 2,057.00 -6.37 -0.31%
NASDAQ 4,747.7240 -15.50 -0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs